RCKT in the 13F filings
Rocket Pharmaceuticals Inc · CUSIP 77313F106
- Quarter end
- 31 Mar 2024
- the date the book describes
- Filed
- 15 May 2024
- latest of these filings; the earliest 15 May 2024
- Managers listing it
- 3
- at least, of 95 tracked, among listed positions
- Comparable managers
- 93
- filed both Q4 2023 and Q1 2024; 3 listed it in both
- Shares listed
- 15,650,427
- combined, among listed positions
- Reported value
- $422m
- combined, at the quarter end
Among the 93 comparable managers: 2 buyers (opened or added shares) and 1 seller (trimmed or exited), at least, among listed positions. Their net change in shares was +2,468,908.
Managers listing RCKT in Q1 2024
3 of 3 holders
| Action | Filing | |||||
|---|---|---|---|---|---|---|
| Wellington Management Group LLP | 9,156,099 | $247m | under 0.1% | Added | +958,553 | 15 May 2024 (the filing on sec.gov) |
| Maverick Capital Ltd | 3,888,312 | $105m | 1.97% | Trimmed | -145,756 | 15 May 2024 (the filing on sec.gov) |
| Janus Henderson Group Ltd | 2,606,016 | $70m | under 0.1% | Added | +1,656,111 | 15 May 2024 (the filing on sec.gov) |
Largest increases and reductions, by shares
Increases
- Janus Henderson Group Ltdexisting position · 2,606,016 shares now+1,656,111
- Wellington Management Group LLPexisting position · 9,156,099 shares now+958,553
Reductions
- Maverick Capital Ltdexisting position · 3,888,312 shares now-145,756
New positions and exits
New (0)
No new position among listed positions.
Exited (0)
No exit shown by a manager’s own filing.
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q1 2018 | 2 | $1.3m | n.a. | n.a. |
| Q4 2018 | 1 | $1.5m | n.a. | n.a. |
| Q2 2019 | 1 | $2.7m | n.a. | n.a. |
| Q4 2019 | 1 | $8.1m | n.a. | n.a. |
| Q4 2020 | 3 | $228m | n.a. | n.a. |
| Q1 2021 | 2 | $178m | n.a. | n.a. |
| Q2 2021 | 3 | $210m | n.a. | n.a. |
| Q3 2021 | 1 | $50m | n.a. | n.a. |
| Q4 2021 | 1 | $41m | n.a. | n.a. |
| Q1 2022 | 3 | $37m | n.a. | n.a. |
| Q2 2022 | 2 | $36m | n.a. | n.a. |
| Q3 2022 | 2 | $42m | n.a. | n.a. |
| Q4 2022 | 2 | $71m | n.a. | n.a. |
| Q1 2023 | 3 | $86m | n.a. | n.a. |
| Q2 2023 | 1 | $87m | n.a. | n.a. |
| Q3 2023 | 2 | $280m | n.a. | n.a. |
| Q4 2023 | 3 | $395m | 2 | 1 |
| Q1 2024 | 3 | $422m | 2 | 1 |
| Q2 2024 | 4 | $357m | 3 | 1 |
| Q3 2024 | 4 | $330m | 3 | 1 |
| Q4 2024 | 5 | $320m | 5 | 0 |
| Q1 2025 | 1 | $35m | 1 | 0 |
| Q2 2025 | 2 | $21m | 2 | 0 |
| Q3 2025 | 2 | $28m | 1 | 0 |
| Q4 2025 | 2 | $9.6m | 14 | 12 |
| Q1 2026 | 2 | $13m | 15 | 14 |
| Q2 2026 | 2 | $14m | 13 | 11 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
RCKT and LLY →RCKT and JNJ →RCKT and VRTX →Choose a stock to compare with RCKT →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own RCKT, latest filings →Back to the 13F Explorer →